– CNBC
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
7 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:CPRX) over the past quarter, offering a…
Related Posts
John Bean Unveils Revised Ambitious €3.5B Marel Takeover Offer – What’s On The Cards?
John Bean Technologies exceeds FY23 expectations with adjusted EPS of $4.05-$4.15, citing strong operational execution and revenue growth. The company plans a voluntary takeover offer for Marel hf, anticipating annual synergies of $125 million post-merger.
Danimer Scientific Announces Proposed Pro-Rata Distribution Of Warrants To Purchase Common Stock
Danimer Scientific, Inc. (NYSE:DNMR) ("Company" or "Danimer Scientific"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced a proposed
Goldman Sachs Maintains Buy on Capri Holdings, Lowers Price Target to $59
Goldman Sachs analyst Brooke Roach maintains Capri Holdings (NYSE:CPRI) with a Buy and lowers the price target from $69 to $59.